China Shineway Pharmaceutical Group Limited
CSWYF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $3,491 | $287 | $145 | $175 |
| % Growth | 1,115.8% | 98% | -16.9% | – |
| Cost of Goods Sold | $875 | $71 | $36 | $43 |
| Gross Profit | $2,615 | $216 | $109 | $131 |
| % Margin | 74.9% | 75.3% | 75.1% | 75.2% |
| R&D Expenses | $94 | $6 | $4 | $4 |
| G&A Expenses | $271 | $20 | $13 | $10 |
| SG&A Expenses | $1,756 | $133 | $78 | $85 |
| Sales & Mktg Exp. | $1,485 | $112 | $66 | $75 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,850 | $139 | $73 | $87 |
| Operating Income | $765 | $77 | $26 | $43 |
| % Margin | 21.9% | 26.9% | 18.1% | 24.4% |
| Other Income/Exp. Net | $262 | $41 | $13 | $6 |
| Pre-Tax Income | $1,027 | $119 | $39 | $49 |
| Tax Expense | $273 | $32 | $6 | $13 |
| Net Income | $754 | $86 | $33 | $36 |
| % Margin | 21.6% | 30% | 22.6% | 20.5% |
| EPS | 0.996 | 0.114 | 0.043 | 0.047 |
| % Growth | 772% | 165% | -8.9% | – |
| EPS Diluted | 0.996 | 0.114 | 0.043 | 0.047 |
| Weighted Avg Shares Out | 755 | 755 | 759 | 756 |
| Weighted Avg Shares Out Dil | 755 | 755 | 755 | 755 |
| Supplemental Information | – | – | – | – |
| Interest Income | $177 | $0 | $3 | $4 |
| Interest Expense | $5 | $1 | $0 | $0 |
| Depreciation & Amortization | $58 | $11 | $5 | $6 |
| EBITDA | $1,132 | $88 | $32 | $49 |
| % Margin | 32.4% | 30.7% | 21.9% | 28% |